Glycobiology Market Size (2024 - 2029)

The glycobiology market is projected to experience significant expansion over the forecast period, driven by increased research and development activities focused on glycomes and advancements in technology for analyzing glycans and proteomes. The market's growth trajectory is influenced by the critical role of glycans in various biological processes, including their involvement in hereditary diseases and cancer development. The COVID-19 pandemic has notably impacted the market, but it is now recovering and expected to grow robustly.

Market Size of Glycobiology Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Glycobiology Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 0.62 Billion
Market Size (2029) USD 1.24 Billion
CAGR (2024 - 2029) 14.87 %
Fastest Growing Market Europe
Largest Market North America

Major Players

Glycobiology Market Major Players

*Disclaimer: Major Players sorted in no particular order

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Glycobiology Market Analysis

The Glycobiology Market size is estimated at USD 0.62 billion in 2024, and is expected to reach USD 1.24 billion by 2029, growing at a CAGR of 14.87% during the forecast period (2024-2029).

Several vaccine development efforts related to COVID-19 primarily focused on the coronavirus transmembrane spike (S) glycoprotein, which extends from the viral surface and mediates host cell entry. A critical step in this crosstalk between the virus and the host cell is the binding of S-glycoprotein to the ACE2 receptor on the surface of human cells. Both S-glycoprotein and ACE2 receptors are known to be extensively glycosylated, i.e., they contain covalently linked complex oligosaccharides called glycans. This makes a promising research path on glycans during the pandemic. Many research studies proved that glycans are crucial in COVID-19 infection. A March 2021 research study by researchers at RIKEN Center for Computational Science (R-CCS) found that glycans sugar molecules play an essential role in the structural changes that occur when the virus causes COVID-19 to invade human cells.

According to a study published in the Journal of Molecular Biology in June 2021, glycan-binding proteins are involved in both human defense and the ability of viruses to infect. Drugs that should be considered for COVID-19 prevention and treatment include glycan antigens, anti-glycan antibodies, glycan-binding proteins, lectin inhibitors, polysaccharides, glycosidase inhibitors, and glycosides. Thus, the above-mentioned factors state that the global glycobiology market was significantly impacted by the COVID-19 pandemic. However, the market is currently gaining its pre-pandemic nature and is expected to witness healthy growth over the forecast period.

The major factor responsible for the growth of the glycobiology market is the increasing research and development activities about glycomes and emerging technology for analyzing glycans and proteomes. Glycans, generally present on the cell surface, play a crucial role in the body system. They are responsible for many hereditary diseases and have a vital role in cancer development. In December 2021, Griffith University's Institute for Glycomics of Australia received a grant of USD 1.80 million from the Australian Cancer Research Foundation (ACRF) to establish the ACRF International Centre for Cancer Glycomics. In August 2022, GlycoNet, a pan-Canadian network of Centers of Excellence centered at UAlberta, received a USD 10.68 million investment from the Canadian Foundation for Innovation's Major Science Initiative Fund to continue its mission of researching glycomics for the benefit of human health.

Thus, owing to the above-mentioned factors, the market studied is believed to witness strong growth over the forecast period.

Glycobiology Industry Segmentation

As per the scope of the report, glycobiology is the study of carbohydrates and carbohydrate-containing biomolecules in biological processes. This study is used in diagnostics, drug discovery research, immunology, oncology, and other applications. The glycobiology market is segmented by product (enzymes, instruments, and kits and reagents), application (diagnostics, drug discovery and development, oncology, immunology, and other applications), end user (pharmaceutical and biotechnology companies, contract research organizations, and other End users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 different countries across major regions. The report offers all values in USD million for the above segments.

By Product
Enzymes
Instruments
Kits and Reagents
By Application
Diagnostics
Drug Discovery and Development
Oncology
Immunology
Other Applications
By End User
Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Glycobiology Market Size Summary

The glycobiology market is poised for significant growth, driven by increasing research and development activities focused on glycomes and the advancement of technologies for analyzing glycans and proteomes. Glycans, which are complex oligosaccharides present on cell surfaces, play a crucial role in various biological processes, including hereditary diseases and cancer development. The COVID-19 pandemic highlighted the importance of glycans in viral infection mechanisms, leading to a surge in research and interest in glycobiology. This has resulted in substantial funding and grants for research initiatives, such as those by Griffith University's Institute for Glycomics and GlycoNet, which are expected to propel the market forward. The market's recovery to pre-pandemic levels and its anticipated robust growth are further supported by the increasing burden of chronic diseases, which necessitates the development of new drugs and therapies leveraging glycan modifications.

The market landscape is moderately competitive, with numerous companies actively contributing to its expansion through strategies like new product launches, mergers, acquisitions, and collaborations. Key players such as Agilent Technologies, Waters Corporation, Shimadzu Corporation, Merck KGaA, and New England Biolabs are at the forefront of these efforts. Innovations in glycobiology, such as the development of glycan-based vaccines and drug delivery systems, are gaining traction, particularly in regions like North America, where government funding and research initiatives are robust. The establishment of new facilities and programs, such as those by Vector Laboratories and Cold Spring Harbor Laboratory Press, underscores the growing focus on glycobiology. These developments are expected to enhance the market's growth trajectory, with companies like Thermo Fisher Scientific and Bruker introducing advanced technologies for spatial multi-omics applications, further solidifying the market's potential.

Explore More

Glycobiology Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Government and Private Funding for Glycomics and Proteomics Research

      2. 1.2.2 Growing R&D Expenditures by Pharmaceutical and Biotechnology Companies

    3. 1.3 Market Restraints

      1. 1.3.1 High Product Cost

      2. 1.3.2 Low Availability of Skilled Professionals

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size - Value in USD million)

    1. 2.1 By Product

      1. 2.1.1 Enzymes

      2. 2.1.2 Instruments

      3. 2.1.3 Kits and Reagents

    2. 2.2 By Application

      1. 2.2.1 Diagnostics

      2. 2.2.2 Drug Discovery and Development

      3. 2.2.3 Oncology

      4. 2.2.4 Immunology

      5. 2.2.5 Other Applications

    3. 2.3 By End User

      1. 2.3.1 Pharmaceutical and Biotechnology Companies

      2. 2.3.2 Contract Research Organizations

      3. 2.3.3 Other End Users

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Glycobiology Market Size FAQs

The Glycobiology Market size is expected to reach USD 0.62 billion in 2024 and grow at a CAGR of 14.87% to reach USD 1.24 billion by 2029.

In 2024, the Glycobiology Market size is expected to reach USD 0.62 billion.

Glycobiology Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)